Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.42 |
| ▸ | HTR3B | O95264 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 4/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12332467 | 0.84 | CTSL (0.42) | MAPTALDH1A1LMNAGAAALOX12 | |
| SCHEMBL18004027 | 0.84 | TAS1R3 (0.36) | MAPTALDH1A1LMNAGAAALOX12 | |
| SCHEMBL12127523 | 0.79 | ALDH1A1 (0.44) | MAPTALDH1A1LMNAGAAALOX12 | |
| SCHEMBL628459 | 0.79 | ALDH1A1 (0.46) | MAPTALDH1A1LMNAGAACTSL | |
| SCHEMBL70253 | 0.75 | PARP1 (0.63) | MAPTALDH1A1GAATSHRHTR3E | |
| SCHEMBL12127674 | 0.74 | MAOA (0.46) | MAPTALDH1A1LMNAALOX12CYP3A4 | |
| SCHEMBL12127806 | 0.74 | GRIN2B (0.44) | MAPTALDH1A1GAA | |
| SCHEMBL12127370 | 0.74 | PARP10 (0.40) | MAPTALDH1A1LMNAGAAALOX12 | |
| SCHEMBL9586261 | 0.74 | TPMT (0.55) | MAPTALDH1A1LMNAGAAALOX12 | |
| SCHEMBL3597105 | 0.74 | ATP4A (0.38) | MAPTALDH1A1LMNAGAAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550757-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550757-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2542089-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011109799-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | MAPT 2798/4885ALDH1A1 4088/4885LMNA 158/4885 |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | MAPT 2798/4885ALDH1A1 4088/4885LMNA 158/4885 |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | MAPT 4292/4885ALDH1A1 971/4885LMNA 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.